Synthesis and Analytical Evaluation of Folate Conjugates for Use in Cancer Cell Detection by Koshiya, Pradipkumar
Governors State University
OPUS Open Portal to University Scholarship
All Capstone Projects Student Capstone Projects
Spring 2011
Synthesis and Analytical Evaluation of Folate
Conjugates for Use in Cancer Cell Detection
Pradipkumar Koshiya
Governors State University
Follow this and additional works at: http://opus.govst.edu/capstones
Part of the Analytical Chemistry Commons, Diagnosis Commons, and the Other Analytical,
Diagnostic and Therapeutic Techniques and Equipment Commons
For more information about the academic degree, extended learning, and certificate programs of Governors State University, go to
http://www.govst.edu/Academics/Degree_Programs_and_Certifications/
Visit the Governors State Analytical Chemistry Department
This Project Summary is brought to you for free and open access by the Student Capstone Projects at OPUS Open Portal to University Scholarship. It
has been accepted for inclusion in All Capstone Projects by an authorized administrator of OPUS Open Portal to University Scholarship. For more
information, please contact opus@govst.edu.
Recommended Citation
Koshiya, Pradipkumar, "Synthesis and Analytical Evaluation of Folate Conjugates for Use in Cancer Cell Detection" (2011). All
Capstone Projects. 42.
http://opus.govst.edu/capstones/42
 1 
Synthesis and Analytical Evaluation of Folate Conjugates for Use in Cancer 
Cell Detection  
A Project 
 
Submitted 
 
to 
 
Governors State University 
 
By 
 
Pradipkumar Koshiya 
 
 
In Partial Fulfillment of the 
 
Requirements for the Degree 
 
Of 
 
Masters in Science 
 
  May 2011 
 
Governors State University 
 
University Park, Illinois 
08 Fall 
 2 
 
 
 
 
 
 
Dedicated to 
My Parents, Friends & Family 
 
 
 
 
 
 
 
 
 
 
 3 
 
Acknowledgements 
 
 
 
I am thankful to Dr Walter Henne, who helped me to develop an understanding of 
the project, and who gave me encouragement, guidance and invaluable support from the 
start to the end of my research. 
Deepest gratitude to my supervisory committee, Dr Patty Fu-Giles and Prof. 
Stephen Kent. Without their guidance and support this project would not have been 
successful.  
Special thanks to my friends, Yogesh Radadiya, Rakesh Desai and Hardik Khared, who 
have offered support through out my project work and who have always been there 
whenever I had difficulties.   
Also, this dedication goes to my parents whose encouragement has been with me 
all the time and without whose support I could not approach this work and could not 
pursue my degree. 
 
 
 
 
 4 
 
Table of Contents 
Abstract: ....................................................................................................................................... 5 
Introduction: .............................................................................................................................. 6 
Folate and its role: .............................................................................................................................. 6 
Folate receptor pathway: ................................................................................................................. 6 
Folate-conjugate dye - DyLightTM488: ......................................................................................... 6 
Mouse L1210 Leukemia model: ........................................................................................................ 7 
Materials and Instrumentation: .......................................................................................... 7 
Materials: ............................................................................................................................................... 7 
Instruments: ......................................................................................................................................... 7 
Method and Analysis: .............................................................................................................. 8 
Synthesis of Folate-DyLightTM 488 ................................................................................................ 8 
L1210 mouse leukemia cell development and observation: .............................................. 8 
Binding of purified Folate DyLight 488 with incubated L1210 mouse Leukemia cells
 ................................................................................................................................................................ 10 
Result and Discussion: ......................................................................................................... 11 
Analysis and purification of folate conjugated dye 488 by HPLC: .................................. 11 
Analysis of pure compound by LC-MS: ..................................................................................... 11 
Conclusion: ............................................................................................................................... 12 
Acknowledgement: ............................................................................................................... 13 
References:............................................................................................................................... 13 
List of Figures: ......................................................................................................................... 15 
Figure 1: Figure demonstrates the high affinity folate conjugation on folate 
receptor (FR)+. ................................................................................................................................. 15 
Figure 2: Mini centrifuge (Fisher Scientific) .......................................................................... 16 
    Figure 3: Magnetic stirrer (ColeParmer)……………………………………………………………….16       
Figure 4: Water Jacketed Incubator for incubation of conjugated dye. ....................... 17 
Figure 5: Schematic presentation of conjugation of folate cysteine with Dylight 488        
Maleimide ........................................................................................................................................... 18 
Figure 6: Chromatogram of Folate-DyLightTM 488. ........................................................... 19 
Figure 7: DAD absorption spectrum of folate DyLight 488............................................... 20 
Figure 8: Mass spectrum of folate-DyLightTM 488. ............................................................. 21 
Figure 9: Establishment of FR+ L1210 mouse cancer cells. ............................................. 22 
 
 
 5 
Abstract: 
Folate-targeted dyes have been used for the detection of tumor tissue and isolated 
cancer cells in both the animal tumor models as well as in human cancer patients. Folate 
receptors (FR) are abundantly present on several cancerous cell types but they are found 
less in normal human cells
1
. There are several imaging agents that can be linked with 
folic acid and used for the detection of tumor
2-3
. These imaging agents could be protein 
toxins, chemotherapeutic agents, gene therapy vectors, oligonucleotides, radioimaging 
agents, magnetic resonance imaging contrast agents and liposomes with entrapped drugs, 
radiotherapeutic agents and/or immunotherapeutic agents
4
. This research showed that 
targeting one of these agents, the fluorescent dye, Dylight 488, produced more specific 
and sensitive imaging of malignant cells for diagnostics purpose of cancer detection
5
.   
  In the present research, we synthesized folate-conjugate dye, Folate-
DyLight
TM
488, using simple methods and minimal efforts. The research involved 
purification of synthesized Folate-Conjugate, Folate-DyLight
TM
488 by HPLC followed 
by the analysis of purified Folate-DyLight
TM
488. The purified Folate-DyLight
TM
488 was 
first analyzed using UV/VIS micro-plate reader as well as LC-DAD and finally with the 
LCMS. Mass Spectroscopy eventually confirmed the dye. Ultimately, the dye was 
lyophilized and used for the cancer cell detection by fluorescent microscope.  
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Introduction: 
Folate and its role: 
Folate belongs to the vitamin B group and generally termed as folic acid.  It is 
involved the one carbon transfer reaction, which helps for DNA synthesis and replication, 
cell division and it also plays an important role in methylation
6-7
. Two types of folate 
binding proteins are present on the cell; one with low affinity binder, reduced folate 
carrier (RFC), responsible for the most of folate transport across the cell membrane and 
the other is high affinity binder, folate receptor (FR), which mediate folate uptake by 
endocytosis
6, 8-9
. Folate receptor mediated endocytosis is a simple strategy to transport 
folate dye because of the over expression of the folate receptor on cancer cells
3, 10
.  
Folate receptor pathway: 
Two different systems are exists for the transportation of folates
11
: 
i) Membrane bound Folate Receptor (FR- and FR-) – linked to cell surface via a 
glycosylphosphatydilinositol (GPI) anchor 20, which transport the folates by receptor 
mediated endocytosis
12-15
. 
ii) Reduced Folate Carrier (RFC) – Transport of folate was done by anion exchange into 
the cytoplasm. Unlike FR, RFC transport folates by binding it and carrying folate into the 
cell
16-17
.   
Folate-conjugate dye - DyLight
TM
488: 
For the screening of cancer cells we have used DyLight
TM
488, which has a greater 
photostability than other commercial fluorescent dyes available in 488-range dyes. Also it 
has a pH insensitivity ranging from 4-9 and available at a lower cost. DyLight
TM
488 is 
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available as labeling agent, used in fluorescent microscopy, and as a conjugates of 
secondary antibodies in western blotting and ELISA. 
Mouse L1210 Leukemia model: 
The first screening model used at national cancer institute (NCI) was in vivo L1210 
and P388 murine leukemia. From 1955 until 1975, the mouse L1210 model has been used as 
a model for the treatment and detection of blood cancers. Moreover, the human leukemia 
has also been useful for prediction of the drugs that are effective against such diseases. 
However, this model is sometimes proved poor a predictor for cancers because of the 
difference in physiological activity of mouse and human tumor.   
Materials and Instrumentation: 
Materials:  
DyLight
TM
488 Maleimide (Thermo scientific, Lot# LC1294236), Folate Cysteine, 
Dimethylsulfoxide (DMSO, from Sigma-Aldrich, Batch# 11696DK), 99% 
Diisopropylethylamine- [(CH3)2CH]2NC2H5 (DIPEA, from Sigma-Aldrich, Batch# 
33396AK, MW:129.24 gm/mol), Sodium bicarbonate (buffer), L1210 Mouse leukemia 
cells, RPMI medium 1640 (GIBCO, Lot# 714204), Folic acid, Phosphate buffer saline 
(PBS) 
Instruments: 
HPLC (Hewlett Packard series 1050) with installed Zorbax column (3.5 µm, 4.6x 
150mm) and C18 column (5µm, 10x 250 mm), Agilent LC-MSD trap 1100 series with 
Agilent Eclipse XDB-C18 column, Epoch Biotek microplate spectrophotometer, Water 
Jacketed Incubator (Fisher Scientific, Model 3326), Mini Centrifuge (Fisher Scientific), 
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Refrigerated condensation Trap RT100, Cole Parmer (Model 84000-00), epi-fluorescence 
microscope. 
Method and Analysis: 
Synthesis of Folate-DyLight
TM 
488  
Initially 1 mg of DyLight 488 (stored at -20 C), and 2 mg of folate cysteine were 
weighed and mixed together. Then 200µl of dimethylsulfoxide (DMSO), a polar aprotic 
solvent, was added to dissolve the solid mixture. Finally, 2 µl of Diisopropylethylamne 
(DIPEA), an organic reagent, was added and the mixture was left to stir overnight. The 
sample mixture was analyzed through HPLC using Zorbax column and purification was 
done with column C18.  
For LCMS, Eclipse XDB-C18 column was used. The sample was run in negative 
mode with methanol and water as mobile phase. 
Sample info: 10 l of purified Folate-DyLightTM488 (200 ppm)  
Flow rate: 0.5 ml/min 
Scan range: 600-1000 m/z 
Method: waltLCDADMS.m 
L1210 mouse leukemia cell development and observation: 
L1210 mouse leukemia cells were grown and folate deficient RPMI (supplement 
with 10% fetal bovine serum and 1% streptomycin-penicillin) media to the level of 
500,000 – 1 million cells per ml. The cells were incubated in the presence of 100 nmolar 
of folate-Dylight 488 with and without the presence of excess folic acid that will be 1000 
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fold excess. The incubation was done for 30 mins at the temperature of 37’C and samples 
were read on fluorescence microscope with fluorescence filters. 10-15 ul of cell 
suspension was mounted on glass slides for observation.  
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Binding of purified Folate DyLight 488 with incubated L1210 mouse Leukemia cells 
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Result and Discussion: 
Analysis and purification of folate conjugated dye 488 by HPLC:  
The analysis of Folate-Dylight 488 was done using HPLC. Sodium bicarbonate 
buffer (10 mM) and acetonitrile were used as a mobile phase solvent, flow rate was 1 
ml/min and total run time was 60 mins. 10 ul of 5-fold sample was injected at the 
wavelength of 280 nm and initially the peak was seen at 16.85 min, which was DMSO. 
Then the other peak was seen at 23.25 min, which was the combination of our folate dye 
and folate cysteine. Purification of conjugated dye was then accomplished using 
preparative column to purify the suspected folate conjugate. We knew that our sample 
was eluted between 23.00 min and 25.00 min. At that time, the fraction was collected for 
LC-MS analysis.    
Analysis of pure compound by LC-MS: 
In LC-MS, we started with injection of purified conjugate sample (30 uL or 200 
ppm) in positive ion mode, but we could not get any resultant peak after 1100 m/z. As a 
result, we tried in negative ion mode. In negative ion mode methanol and water were 
used as a mobile phase and we obtained a peak at 3.11 mins. The chromatogram in the 
figure 6 shows a sharp peak of purified folate-Dylight 488. For more confirmation, DAD 
absorption spectrum was obtained which confirm the peak at 3.11 mins in chromatogram. 
DAD spectrum has scan range of 200-800 nm and Figure 7 Shows the DAD absorption 
spectrum.  
Mass spectrometry finally confirms the product by showing a peak at 447.0 m/z. 
Since Folate-conjugated Dylight 488 has molecular weight of 1343.0, the molecular ion 
peak was most likely a multi-charged species. Using the known molecular weight, we 
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calculated that we obtained a triply charged ion peak at 447.0 (m/3z, M-3H
+
). We can 
confirm the molecular ion peak (1343.0 m/z) by multiplying triply charged ion peak (at 
447.0 m/z) times three and adding 3 H atoms (3). This value was near the integer mass 
match. From the above analysis we confirm that Folate-Dylight 488 was present and 
ready for cancer cell detection.   
After analysis of compound by LC-MS it was subjected to lyophilisation to 
remove excess water from the sample. Then the sample was diluted with 1 mL PBS and 
placed in the microplate reader to measure the absorbance at 493 nm. And from the 
absorbance (after path length corrected, 1.257), concentration of the sample was 
calculated as 1.62x10-4 using the known extinction coefficient of 70 M-1cm-1.Finally, 
L1210 mouse leukemia cells stained with the folate-conjugated dye was observed on epi-
fluorescence microscope and the cancer cells were easily detectable with conjugated dye 
on it (See Figure 9).  
Conclusion: 
We have successfully completed the analysis and purification of folate Dylight 
488 by reverse phase HPLC. LC-MS confirms the presence of folate conjugate dye by 
showing absorption spectrum and the triply charged (m/3z, M-3H+) ion peak in negative 
ion mode. The molecular ion was also monitored in positive ion mode but not seen at 
1343 m/z. Finally, we demonstrated the binding of conjugated dye to L1210 mouse 
leukemia cells and confirmed the specificity by a control pre-incubated with excess free 
folic acid  (See Figure 9). 
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Figure 1: Figure demonstrates the high affinity folate conjugation on folate receptor 
(FR)+. 
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     Figure 2: Mini centrifuge (Fisher Scientific)  
                                                              
                Figure3: Magnetic stirrer (Cole Parmer) 
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                   Figure 4: Water Jacketed Incubator for incubation of conjugated dye. 
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Figure 5: Schematic presentation of conjugation of folate cysteine with Dylight 488        
Maleimide to yield Folate Dylight 488  
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Figure 6: Chromatogram of Folate-DyLightTM 488. Peak shown at 3.11 mins 
indicates the measured absorbance at 280 nm on Agilent LC-MSD trap 1100 sereis. 
 
 
 
 
 
 
 20 
 
 
 
                      Figure 7: DAD absorption spectrum of folate DyLight 488. 
 
 
 
 
 
 
 
 
 21 
 
 
 
 
 
       Figure 8: Mass spectrum of folate-DyLightTM 488. The data indicate the triply    
       charged (m/3z, M-3+) molecular ion peak obtained by Agilent LC-MSD trap 
       1100 series using XDB C18 column.  
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Figure 9: Establishment of FR+ L1210 mouse cancer cells. Cells were grown in 
folate deficient media for a total of 6 passages. Using a folate targeted dye (folate 
Dylight 488, developed “in Lab”). Cells were stained in absence and presence of an 
excess of folic acid competitor (epi-fluorescense panel B and D, respectively).  
Together, these data demonstrate both FR mediated uptake and folate targeted 
specificity. Panels A and C are the corresponding phase contrast images at 1000x 
and 250x magnification, respectively.   
 
 
 
